A rapid reform to healthcare systems, public policy and attitude in society would be required to address burden of Alzheimer’s disease in population, even as medications and blood tests present a potential in diagnosis and treatment, researchers say in a Lancet Series.
Alzheimer’s disease — the most common form of dementia — is an ageing-related neurological disorder which steadily impacts one’s memory and thought processes, eventually interfering with daily activities.
Describing new treatments and diagnostic methods for the condition in a series of three papers in The Lancet journal, the international team of researchers said that medications — lecanemab and donanemab — could slow down Alzheimer’s disease from advancing.
The drugs, which target specific proteins in a cell, have shown an efficacy comparable to that of drugs for cancer and autoimmune disorders such as rheumatoid arthritis and multiple sclerosis, the team said.
They added that however, high costs of medicines, .​A rapid reform to healthcare systems, public policy and attitude in society would be required to address burden of Alzheimer’s disease in population, even as medications and blood tests present a potential in diagnosis and treatment, researchers say in a Lancet Series.
Alzheimer’s disease — the most common form of dementia — is an ageing-related neurological disorder which steadily impacts one’s memory and thought processes, eventually interfering with daily activities.
Describing new treatments and diagnostic methods for the condition in a series of three papers in The Lancet journal, the international team of researchers said that medications — lecanemab and donanemab — could slow down Alzheimer’s disease from advancing.
The drugs, which target specific proteins in a cell, have shown an efficacy comparable to that of drugs for cancer and autoimmune disorders such as rheumatoid arthritis and multiple sclerosis, the team said.
They added that however, high costs of medicines, . ​Latest News [ SOBAN NEWS: International and National ]
